CD68+ cell numbers were reduced in both early- stage (CRC I, II; p < 0.05) and late-stage (CRC III, IV; p < 0.0001) tumors, whereas CD163+ cell counts were similarly decreased in early- and late-stage CRC (p < 0.05 and p < 0.01, respectively) (Figure 4D). Here, CD163 is linked to colorectal carcinoma.